Efficacy and safety of adalimumab 80 mg in the treatment of psoriasis: a bicentric retrospective study.

Adalimumab (ADA) is a recombinant human monoclonal antibody indicated for the treatment of psoriasis that specifically inhibits tumor necrosis factor. Until recently we only had the presentation of 40 mg of ADA, being the standard dose in adults an initial administration of 80 mg, followed by 40 mg every 2 weeks. Newly the presentation of 80 mg of ADA has been commercialized, allowing the administration of the standard dose or a higher dose, with fewer injections. In this study, we retrospectively studied 11 patients with psoriasis who have received treatment with the presentation of 80 mg of ADA in two dermatology departments of two hospitals in Spain since its commercialization until June 2019. At the end of the study, an improvement in the mean final Psoriasis Area Severity Index (PASI) of all patients was observed, without any patient presenting any adverse effects. This study shows the efficacy and safety of 80 mg of ADA in a sample of 11 patients with psoriasis.

Un caso de prurito incoercible / A case of incoercible pruritus

No disponible

Calcifilaxia no urémica en una paciente con artritis reumatoide / Non-uremic calciphylaxis in a female patient with rheumatoid arthritis

No disponible

Omalizumab in chronic urticaria: a retrospective series of 15 cases.

Omalizumab is a monoclonal anti-IgE antibody approved for the treatment of severe allergic asthma. There is increasing evidence in the literature of its usefulness in chronic urticaria. Herein, we report a retrospective case series of 15 patients with chronic idiopathic urticaria treated with omalizumab. We reviewed their medical records to assess the improvement achieved after 3 and 6 months of treatment. Complete response was defined as symptom disappearance that could be followed by discontinuation of antihistamines, and partial response as symptom improvement, but with symptom worsening when attempting to discontinue antihistamines. After 3 months of treatment, 12 patients responded, with partial response in 9 and complete response in 3. At 6 months, 8 of 10 patients continuing on omalizumab had a complete response and 2 a partial response. The results of the present retrospective series show the effectiveness of omalizumab in most treated patients, which is consistent with other recently published series and studies. These data support its role in the management of patients with chronic urticaria refractory to conventional treatments.

Efficacy and safety of clinical use of etanercept for the treatment of moderate-to-severe psoriasis in Spain: results of a multicentric prospective study at 12 months follow-up.

BACKGROUND: The efficacy of etanercept in the treatment of psoriasis has been demonstrated in several clinical trials, but information regarding results derived from prospective observational studies in clinical practice is scarce. OBJECTIVES: To evaluate the efficacy and safety of etanercept administration according to routine clinical use in moderate-to-severe plaque psoriasis. MATERIALS AND METHODS: Postauthorization, prospective study, carried out at 59 dermatology units in Spain. Patients diagnosed with moderate-to-severe plaque psoriasis received etanercept during a 12-month period. RESULTS: Altogether, 444 patients were enrolled. Overall, 325 patients (73.2%) initiated etanercept treatment at a dose of 50 mg twice weekly; 96 patients (21.6%) received etanercept as a continuous regimen for the entire study period, and 348 patients (79.4%) an intermittent regimen. Among these, 185 patients (41.6% overall) received one course of treatment, stopped at various study points and did not restart etanercept treatment, whereas the remaining 163 patients (36.7% overall) stopped etanercept treatment, lost response, relapsed and were retreated. Most patients who interrupted etanercept treatment did so at month 6. Altogether, 79.7% of patients completed the study period. Etanercept treatment resulted in significant improvement in disease activity. A Psoriasis Area and Severity Index (PASI) 75 response was achieved by 76.1% of patients at month 6. Out of 252 adverse events reported, 31 were considered severe. Three possibly treatment-related malignancies were detected during the study. No opportunistic infections, tuberculosis or demyelinating events were reported. CONCLUSION: The PASI 75 response rate at month 6 in this observational, naturalistic study is similar to those observed in recent published trials with etanercept, and within the range of those reported for other marketed biologicals.

Tratamiento tópico de las micosis cutáneas superficiales / Topical treatments used in superficial cutaneous mycoses

El tratamiento tópico de las micosis cutáneas superficiales comprende una serie de medidas higiénicas, dirigidas a evitar la propagación de la infección y la autocontaminación, además del tratamiento farmacológico. En el presente trabajo se comentan los mecanismos que debe desarrollar el paciente para evitar la diseminación de la infección y acelerar su curación, y las indicaciones del tratamiento exclusivamente tópico. Asimismo, se revisan los principales fármacos antifúngicos tópicos empleados en la actualidad (nistatina, imidazoles, alilaminas, morfolinas y ciclopiroxolamina); se analizan su mecanismo de acción, su espectro de actuación y su presentación. Además, se comentan los diversos esquemas terapéuticos utilizados en el tratamiento tópico de las candidiasis, tanto cutánea como oral y genital, la pitiriasis versicolor y algunas dermatofitosis, en concreto las tineas corporis, pedis, cruris y manum, la onicomicosis y la tiña inflamatoria (AU)

The topical treatment of superficial cutaneous mycoses includes a series of hygiene measures aimed at avoiding spread of the infection and self-contamination, as well as drug therapy. The present article discusses the mechanisms that patients should develop to prevent dissemination of the infection and accelerate its cure, as well as the indications for exclusively topical treatment. In addition, the main topical antifungal agents currently used (nystatin, imidazoles, allylamines, morpholines and ciclopirox olamine) are reviewed and their mechanism of action, spectrum of activity and presentation are discussed. The various therapeutic schemes used in the topical treatment of cutaneous, oral and genital candidiasis, pityriasis versicolor and some dermatophytoses, specifically tinea corporis, pedia, cruris and manum, onychomycosis and inflammatory tinea are also discussed (AU)